NEW YORK (GenomeWeb News) – Gene Bridges said today that Osaka, Japan-based drug developer Takeda Pharmaceutical will use Gene Bridges’ recombination technology under a commercial license agreement through its Japanese distributor, Funakoshi.
Gene Bridges’ Red/ET recombination technology is used to generate target vectors or to modify E. coli chromosomes. The Red/ET technology allows for engineering of molecules, BACs, or the E. Coli chromosome.
Financial terms of the agreement were not released.